Evidence map›Paper›PMID 29523166›Full record

ArticleRetrovirology2018

Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.

Quang N Nguyen, David R Martinez, Jonathon E Himes, R Whitney Edwards, Qifeng Han, Amit Kumar, Riley Mangan, Nathan I Nicely, Guanhua Xie, Nathan Vandergrift and 3 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Quang N NguyenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
David R MartinezDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Jonathon E HimesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
R Whitney EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Qifeng HanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Amit KumarDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Riley ManganDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Nathan I NicelyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Guanhua XieDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Nathan VandergriftDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Justin PollaraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Sallie R PermarDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. sallie.permar@duke.edu.
Duke University · US

Funding

Transmission-blocking potential of novel HIV Env-specific mucosal antibodiesR01AI106380 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2013 to 2017
$3.4M
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0M
Identifying key determinants of IgG transplacental transfer from HIV-infected mothers to their fetusF31AI127303 · NIAID · DUKE UNIVERSITY · PI MARTINEZ, DAVID R. · 2017 to 2018
$50k
National Institute of Allergy and Infectious Diseases F31AI127303NIAID NIH HHS F31 AI127303NIAID NIH HHS R01 AI106380NIH HHS 5R01AI106380-04NIH HHS K01 OD024877
6 · The paper itself

Abstract

backgroundThe initial envelope (Env)-specific antibody response in acutely HIV-1-infected individuals and simian immunodeficiency virus (SIV)-infected rhesus monkeys (RMs) is dominated by non-neutralizing antibodies targeting Env gp41. In contrast, natural primate SIV hosts, such as African green monkeys (AGMs), develop a predominant Env gp120-specific antibody response to SIV infection. However, the fine-epitope specificity and function of SIV Env-specific plasma IgG, and their potential role on autologous virus co-evolution in SIV-infected AGMs and RMs remain unclear.

resultsUnlike the dominant linear gp41-specific IgG responses in RMs, SIV-infected AGMs demonstrated a unique linear variable loop 2 (V2)-specific plasma IgG response that arose concurrently with high gp120-directed antibody-dependent cellular cytotoxicity (ADCC) activity, and SIVsab-infected cell binding responses during acute infection. Moreover, SIV variants isolated from SIV-infected AGMs exhibited high amino acid mutation frequencies within the Env V1V2 loop compared to those of RMs. Notably, the linear V2-specific IgG epitope in AGMs overlaps with an analogous region of the HIV V2 loop containing the K169 mutation epitope identified in breakthrough viruses from RV144 vaccinees.

conclusionVaccine-elicited Env V2-specific IgG responses have been proposed as an immune correlate of reduced risk in HIV-1/SIV acquisition in humans and RMs. Yet the pathways to elicit these potentially-protective V2-specific IgG responses remain unclear. In this study, we demonstrate that SIV-infected AGMs, which are the natural hosts of SIV, exhibited high plasma linear V2-specific IgG binding responses that arose concurrently with SIV Env gp120-directed ADCC-mediating, and SIV-infected cell plasma IgG binding responses during acute SIV infection, which were not present in acutely SIV-infected RMs. The linear V2-specific antibody response in AGMs targets an overlapping epitope of the proposed site of vaccine-induced immune pressure defined in the moderately protective RV144 HIV-1 vaccine trial. Identifying host factors that control the early elicitation of Env V2-specific IgG and ADCC antibody responses in these natural SIV hosts could inform vaccination strategies aimed at rapidly inducing potentially-protective HIV-1 Env-specific responses in humans.

Indexed as

Antibody-Dependent Cell CytotoxicityAcute DiseaseAnimalsAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesChlorocebus aethiopsEpitopesGene Products, envImmunoglobulin GKineticsMutationPeptidesProtein BindingSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAntibodies, NeutralizingAntibodies, ViralEpitopesGene Products, envImmunoglobulin GPeptidesADCCAfrican green monkeyAntibody responseEnvelopegp120gp41Linear peptide antibody responsesNatural SIV hostRhesus monkeySIV

Identifiers

PMID29523166
PMCPMC5845189
OpenAlexW2790675006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.